Posted May. 3, 2012 at 9:13 a.m.
FDA
Research Triangle Park, N.C. — If results of an ongoing phase 3 study don't support the durability of Northera's effect over time, Chelsea Therapeutics "might seek to obtain approval for Northera as an acute rather than a chronic treatment."...
Charlotte firm may seek narrower use for drug to treat Parkinson's sympton
Post a comment
Print this blog postE-mail blog post
Share
FDA
Research Triangle Park, N.C. — If results of an ongoing phase 3 study don't support the durability of Northera's effect over time, Chelsea Therapeutics "might seek to obtain approval for Northera as an acute rather than a chronic treatment."...
WRAL Tech Wire any time: Twitter, Facebook
Copyright 2013 MedCity. All rights reserved.Please log in to view WRALTechWire Insider content
To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.
Please Log In to add a comment.
Best of TechWire Insider
OUR INSIDERS
WRAL TechWire Editor
The Skinny
NC Biotech Center braces for worst as Senate slashes budget, too- ArchiveSocial, a new Durham success story, brings home international award
- Durham's high-tech infrastructure, talent lure Virginia company
- Lenovo acknowledges layoffs in Morrisville as part of shift to 'PC Plus' strategy
- Raleigh-based PRA International eyes public offering
- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows